ESMO Congress 2026

 

Preview news releases and presentations by Dana-Farber Physician-Scientists at this year's ESMO Congress 2026 in Madrid, Spain, October 23 - 27, 2026.


ESMO26: Paolo Tarantino, MD on ADC Resistance in Breast Cancer

Paolo Tarantino, MD, of Dana-Farber Cancer Institute, shows that antibody-drug conjugate (ADC) resistance appears to be driven by complex molecular adaptations beyond target modulation.

ESMO26: Antonio Giordano, MD, PhD, on FOURLIGHT

Antonio Gioradano, MD, presents efficacy and safety of atirmociclib + fulvestrant in HR+/HER2- advanced breast cancer after progressing on prior CDK4/6 inhibitor - data from phase 2 FOURLIGHT-1 study.
Antonio Giordano, MD, PhD

Antonio Giordano, MD, PhD

Medical Oncology

ESMO26: Toni Choueiri, MD, on KEYNOTE-564

Final analysis of the pivotal KEYNOTE-564 trial in kidney cancer presented by Toni Choueiri, MD. After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival and overall survival in high-risk clear-cell renal cell carcinoma.
Toni Choueiri, MD

Toni Choueiri, MD

Medical Oncology

ESMO26: Toni Choueiri, MD on LITESPARK-012

Surprising results in first triplet combination study in advanced kidney cancer presented by Toni Choueiri, MD, at #ESMO26. Dr. Choueiri says even though the combination did not improve efficacy, the findings are important for informing future studies.
Toni Choueiri, MD

Toni Choueiri, MD

Medical Oncology

ESMO26: Vincent Xu, MD on KIM1 in Kidney Cancer

Vincent (Wenxin) Xu, MD , shows among patients with advanced kidney cancer on immunotherapy alone, KIM-1 reductions were seen in immune-inflamed tumors, while no KIM-1 drop was linked to immune-depleted tumors.
Wenxin Xu, MD

Wenxin Xu, MD

Medical Oncology

News Releases

 

Featured Speakers

 

Follow us on social media